T ranscatheter aortic valve replacement (TAVR) is an established alternative for patients with severe aortic stenosis. 1 There is a growing body of evidence demonstrating the durability of current TAVR devices out to 5 years. 2-5 However, it is well known that transcatheter aortic valves (TAVs) can degenerate in a manner similar to surgical bioprostheses. 6
Outcomes of Redo TAVR
Implantation of a second TAV inside a previously implanted TAV (TAV-in-TAV technique) can be an effective technique to promptly treat acute implant failure. 7, 8 In light of the favorable hemodynamic and clinical outcomes associated with the TAV-in-TAV procedure in this setting, it has been argued that this strategy can also be applied in the setting of nonacute TAVR failure because of structural valve degeneration and significant paravalvular regurgitation (PVR). To date, only a few anecdotal reports have demonstrated the feasibility of this approach. [9] [10] [11] [12] The aim of this multicenter international collaboration was to examine the safety and the midterm efficacy of redo TAVR to treat postprocedural and late transcatheter valve failure.
Methods
Data collection was initiated in December 2014, with data from cases of redo TAVR performed before study initiation collected retrospectively and subsequent cases added prospectively. Patients met the inclusion criteria for the study if they were treated with a second TAVR at least 2 weeks after the index procedure. Data were collected from 14 centers across Italy, Germany, Canada, Spain, France, the Netherlands, and the United States using a dedicated case report form. Inconsistencies were resolved directly with local investigators and on-site data monitoring.
All patients gave written informed consent to the TAVR procedure and anonymous data collection and analysis. The authors are solely responsible for the design and conduct of this study, all analyses, drafting, editing of the article, and its final contents.
Statistical Analysis and Definitions
Descriptive statistics are reported as mean±SD for normally distributed continuous variables or as median and 25th-75th percentile (interquartile range) otherwise. Normality of distribution was tested by means of the Kolmogorov-Smirnov test. Absolute and relative frequencies are reported for categorical variables. Continuous variables were analyzed with the Student's t test or Wilcoxon rank-sum test depending on the variable distribution. The χ 2 test and the Fisher exact test were performed for categorical variables. Survival analysis has been performed with the Kaplan-Meier method, reporting incidence of event at each year. A repeated measures analysis with linear contrast at each time point was performed to assess mean aortic gradient change over time. All data were processed using the Statistical Package for Social Sciences, V.20 (SPSS, Chicago, IL). All outcomes were defined according to Valve Academic Research Consortium-2 criteria. 13 Reasons for redo TAVR were categorized into the following: (1) degeneration (defined as severe leaflet calcification or tissue ingrowth causing restrictive leaflet function or leaflet tear) and (2) PVR. Mechanism of TAV degeneration (ie, moderate-severe prosthetic aortic valve stenosis, moderate or severe intraprosthetic aortic valve regurgitation, or combined) was evaluated according to the Valve Academic Research Consortium-2 criteria. Patients with at least moderate degree of both stenosis and regurgitation were included in the combined group. Other patients were categorized according to the primary mechanism of degeneration, either in the stenosis group or in the regurgitation group.
Results

Patient Population
A total of 13 876 patients underwent TAVR at participating centers. Among these, 50 patients (0.4%) underwent redo TAVR. The clinical characteristics of this population are showed in Table 1 . Figure 1 depicts the modes of failure that led to redo TAVR. The indication for redo TAVR was moderate-severe PVR in 25 patients and valve degeneration (new valve stenosis n=9, intravalvular regurgitation n=13, or combined n=3) in the remaining 25 patients. Endocarditis as the cause of intravalvular regurgitation was documented in one patient and suspected in another one (patient was found with leaflet tear, and blood cultures were not performed). Median age was 78 years (interquartile range 71-89), and 16 (32.0%) were females. Mean Society of Thoracic Surgery score was 9.2±8.9%. The mean interval between the index TAVR and redo TAVR was 812±750 days ( Figure 2 ). This interval was significantly lower in patients undergoing redo TAVR for PVR, as compared with patients experiencing structural valve failure (ie, valve stenosis or intravalvular regurgitation; 435±594 versus 1189±706 days; P<0.001). New York Heart Association functional class III or IV dyspnea was the most frequent clinical presentation (n=36, 72.0%), followed by acute heart failure (n=7, 14.0%). In 7 patients (14.0%), symptoms were mild (New York Heart Association class II), and late TAV degeneration was recognized at scheduled echocardiographic follow-up.
Procedure
Procedural data for both index and redo TAVR procedures are reported in Tables 2 and 3 . For the index TAVR, the most common device was CoreValve (Medtronic Inc, Galway, Ireland; N=37, 74.0%), followed by Edwards SAPIEN (N=8, 16.0%), SAPIEN XT (N=2, 4.0%), SAPIEN 3 (N=2, 4.0%; Edwards Lifesciences, Irvine, CA), and Portico (St Jude Medical, Minneapolis, MN; N=1, 2.0%). For redo TAVR, devices used were CoreValve (N=28, 56.0%), SAPIEN XT (N=14, 28.0%), SAPIEN 3 (N=6, 12.0%), Evolut R (Medtronic Inc; N=1, 2.0%), and Lotus valve (Boston Scientific Corporation, Natick, MA; N=1, 2.0%).
In 40 patients (80.0%), redo TAVR was performed using the identical device type or that of the succeeding generation
WHAT IS KNOWN
• The surgical experience has taught us that the main concern with bioprostheses is their limited durability.
• As with surgical bioprostheses, transcatheter aortic valves can be expected to degenerate with time and may eventually require repeat intervention.
• It has been argued that implantation of a second transcatheter valve to treat nonacute transcatheter valve failure because of structural valve degeneration and significant paravalvular regurgitation can be an effective approach.
WHAT THE STUDY ADDS
• Failure of transcatheter prostheses may present as intraprosthetic regurgitation, stenosis, or paravalvular leak.
• In contrast with redo valve surgery, which is technically challenging and carries a higher mortality and morbidity risk than the primary valve procedure, redo transcatheter aortic valve replacement seems to be safe. Outcomes of Redo TAVR ( Figure 3 ). In 43 patients (86.0%), the access routes for the redo procedure were the same as for the first TAVR. When both the index and the redo TAVR were transfemoral (n=40), the redo delivery sheath was most often inserted in the contralateral artery (n=33, 82.5%). Contrast media used for redo TAVR was considerably lower than that used during the first TAVR (188±89 versus 80±46 mL; P<0.001). Balloon postdilation was performed in 17 redo TAVR procedures (34.0%). One case (2.0%) of coronary occlusion after 26-mm SAPIEN XT implantation into a 26-mm Edwards-SAPIEN was reported.
There was one (2.0%) 31-mm CoreValve embolization that occurred in an attempt to treat a failed 31-mm CoreValve. No aortic rupture was documented.
Clinical Outcomes
In-hospital complications of both index and redo TAVR procedures are reported in Table 4 . After redo TAVR, all patients left the hospital alive. During hospitalization, one patient (2.0%) had a nondisabling stroke and another patient (2.0%) had a life-threatening bleeding, whereas new permanent Figure 5 and Table 5 demonstrate TAV performance at followup. Acutely after the first TAVR procedure, mean pressure gradients decreased from 43.7±15.5 mm Hg to 11.9±7.7 mm Hg. At the time of the diagnosis of valve failure, transvalvular gradients were increased in patients with valve degeneration (32.9±21.3 mm Hg), whereas they were consistent with the baseline values in patients presenting with significant PVR (12.3±5.0 mm Hg). After redo TAVR, gradients reduced markedly in patients with valve degeneration (15.1±6.7 mm Hg), even though they were slightly higher as compared with patients who had a second TAV implanted because of PVR (9.0±4.1 mm Hg). Moderately elevated intraprosthetic gradients (mean gradients ≥20 mm Hg) were reported in 5 patients with valve degeneration; in 1 of these, patient-prosthesis mismatch (mean gradient 40 mm Hg, aortic valve area 0.6 cm 2 ) was reported immediately Low TAV implantation was the main mechanism of PVR in 11 cases (55.0%). In the remaining 9 cases (45.0%), the TAV was deployed at the proper height. Redo TAVR was successful at reducing PVR to mild or less in 23 out of 25 patients (92.0%), who presented with significant PVR before the second TAVR procedure. In the 2 cases of residual ≥moderate PVR after
Prosthesis Performance
CoreValve-in-CoreValve, there was severe annular calcification. No cases of valve thrombosis were documented.
Discussion
Previous surgical series have demonstrated that most biological valves degenerate within 10 to 20 years. 14 [2] [3] [4] [5] However, as with surgical bioprostheses, TAVs can be expected to degenerate with time and may eventually require repeat intervention. 16 This multicenter study is the first showing that redo TAVR to treat postprocedural and late transcatheter valve failure is safe and associated with favorable clinical outcomes. Despite the presence of 2 transcatheter prostheses, valve performance was reassuring.
Failure of transcatheter prostheses may present as stenosis (as a consequence of calcification, pannus, or thrombosis) or as intraprosthetic regurgitation (as a consequence of reduced leaflet mobility, tears, or endocarditis). Failure may also present as PVR. 6 Although this is more frequently an acute complication, the importance of regurgitation may only become clinically evident after a period of time. In this population, the mode of failure that led to repeat TAVR procedure was well balanced among valve degeneration (including stenosis and intraprosthetic regurgitation) and PVR.
Selection of the redo TAV varied significantly across centers, suggesting that this procedure requires further study. However, important observations should be made: when a balloon-expandable TAV fails, implantation of a second samesized balloon-expandable TAV was the most commonly used approach. Alternatively, implantation of a mechanical-expandable device may represent a reasonable strategy, performed in only one case. In fact, all cases of failed balloon-expandable valves were treated with the same device type and size, with the exception of one failed 26-mm SAPIEN 3 device treated with a 27-mm Lotus valve. 10 Because of the lack of cases reported in the study, it remains unknown the most appropriate strategy to treat PVR of a well-deployed balloon-expandable TAV. In contrast, this study showed that failed self-expanding TAV (CoreValve and Portico) treatment was more variable, with the same valve implanted in 76%, but a balloon-expandable valve in 28%. In terms of sizing, either the same or the smaller valve size was implanted. In the case of self-expanding TAV degeneration (ie, CoreValve or Portico), a second same-sized or smaller TAV (self-expanding, balloon-expandable, or mechanical-expandable) can be effectively implanted; a smaller TAV must be deployed at the level of the narrowest portion of the first prosthesis to obtain adequate anchoring and sealing. When the mechanism of CoreValve failure is PVR, there are 2 possible scenarios: (1) the PVR is mainly caused by too high or too low valve implantation; in this case, the deployment of any TAV type in the proper position is generally effective in reducing the leak; (2) the PVR is secondary to incomplete frame expansion or suboptimal sealing because of severe annular calcification; in this case, a second TAV with higher radial force (ie, SAPIEN or Lotus) would be preferred to obtain greater expansion and sealing. These considerations need to be proven in future studies.
In general, redo TAVR procedures were safe, with low rates of periprocedural complications and midterm survival comparable to recent TAVR series. We reported one case of coronary obstruction by the native calcified cusp, which occurred after SAPIEN XT implantation inside a degenerated Edwards SAPIEN valve (resolved by urgent stent implantation into the left main) and one case of 31-mm CoreValve embolization in an attempt to treat a failed 31-mm CoreValve. Valve performance compared favorably with other recent TAVR series. Moderately elevated intraprosthetic gradients (mean gradients ≥20 mm Hg) were reported in 5 patients (10%) presenting with stenosis of the fist transcatheter valve, even though in 1 of these, patient-prosthesis mismatch was reported immediately after the first TAVR. This observation differs from valve-in-valve procedures for the treatment of degenerated surgical aortic bioprostheses, in which significantly elevated postprocedural gradients were more common (26.8%), particularly in small (<20 mm) surgical valves (41.2%) and intermediate-sized (21-22 mm) valves (35.8%). 16 The lower profile of the transcatheter valves as compared with the surgical bioprostheses is likely responsible for these more favorable hemodynamic performances. However, it must be underlined that, after redo TAVR, patients with valve degeneration had slightly higher transvalvular gradients as compared with those who had a second TAV implanted because of PVR.
Table 4. In-Hospital Outcomes
The impact of this study on clinical practice is highly relevant for several reasons: first of all, although, to date, redo TAVR is an uncommon procedure, with the growing worldwide adoption of TAVR and its gradual extension to younger and lower-risk population, the volume of patients that in the future may require repeat procedures will increase exponentially; second, in contrast with redo valve surgery, which is technically challenging and carries a higher mortality and morbidity risk than the primary valve procedure, 17, 18 redo TAVR seems to be safe with no increased risk of periprocedural complications. In addition, the sizing process is generally facilitated, and valve deployment is simplified by the presence of the first prosthesis, which serves as a fluoroscopic marker for the landing zone of the second valve. However, 3 main potential concerns associated with redo TAVR still remain. It is unknown whether the presence of 2 valves could affect the long-term durability of the prosthesis; possible leaflet thrombosis in bioprostheses is emerging as an important issue of TAVR. 19 In this series of patients, this was not observed (although no systematic computed tomography assessment was performed). We could speculate that patients with double valves may be more prone to develop this complication. Finally, access to the coronary arteries, particularly after implantation of 2 TAVs that extends into the ascending aorta (ie, CoreValve), needs to be carefully assessed.
Limitations
Limitations of this study include its retrospective design and the small sample size. However, to our knowledge, this is the largest multicenter study to report the outcomes of redo TAVR for the treatment of transcatheter valve failure. In addition, with the available data, we cannot make definite conclusions on the best strategies for device selection in redo TAVR procedures and on long-term survival because patient selection might have biased the excellent outcomes. Indeed, patients in severely reduced clinical condition presenting with TAV failure might not have received any interventional treatment. We cannot exclude leaflet thrombosis as a reversible cause of stenotic degeneration of some of the cases included in the study. 20 Finally, degree and completeness of clinical and echocardiographic follow-up among the entire TAVR populations 
Conclusions
Redo TAVR for the treatment of postprocedural and late occurrence of PVR and TAV prosthesis failure seems to be safe, and it is associated with favorable acute and midterm clinical and echocardiographic outcomes. 
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